Anti-Human PD-L1 & TGF-beta RII Reference Antibody (Retlirafusp Alfa, RUO)
Overview
| Catalog No. |
HV974406 |
| Brand |
abinScience |
| Host species |
Human |
| Tested applications |
WB |
| Species reactivity |
Human |
| Form |
Liquid |
| Storage buffer |
0.01M PBS pH 7.4 |
| Purity |
>95% purity as determined by SDS-PAGE. |
| Clonality |
Monoclonal |
| Isotype |
IgG4-kappa |
| Applications |
ELISA, Bioactivity: FACS, Functional assay, Research in vivo, WB |
| Target |
B7-H1, Programmed cell death 1 ligand 1, PDCD1 ligand 1, PDCD1L1, B7 homolog 1, PDCD1LG1, PDL1, hPD-L1, Programmed death ligand 1, B7H1, PD-L1, CD274, TGFR-2, TbetaR-II, TGF-beta type II receptor, TGFBR2, TGF-beta receptor type-2, TGF-beta receptor type II, Transforming growth factor-beta receptor type II |
| References |
1. Bo Cheng, et al. Anti-PD-L1/TGF-βR fusion protein (SHR-1701) overcomes disrupted lymphocyte recovery-induced resistance to PD-1/PD-L1 inhibitors in lung cancer. Cancer Commun (Lond). 2022 Jan;42(1):17-36. [HV974406] |
| Purification |
Protein A/G purified from cell culture supernatant. |
| Biological activity |
SHR-1701 (10 ug/mL) can inhibit TGF-β signaling pathway, activate PI3K/Akt/Erk signaling pathway, rescue lymphocytes and restore the anti-tumor function of peripheral blood CD8 + T cells in patients with lung cancer [1]. |
| Endotoxin level |
< 10 EU/mg |
| Expression system |
Mammalian cells |
| Accession |
Q9NZQ7 & P37173 |
| Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| Alternative name | SHR-1701 |
| Product Usage Information |
| Application | Dilution |
|---|
| WB | 1:500-1:2000 |
|
| Note |
For research use only. Not suitable for clinical or therapeutic use. |
Images